Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 81

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 81
---
ization expense was $0.4 million for the three months ended June 30, 2025 and 2024, and $1.3 million for each of the nine months ended June 30, 2025 and 2024. None of the intangible assets with definite useful lives are anticipated to have a residual value.The following table presents the estimated future amortization expense related to intangible assets as of June 30, 2025:Amortization ExpenseYear Ending September 30, (in thousands)2025 (remainder)$424 20261,700 20271,700 20281,700 2029795 2030 and thereafter967 Total$7,286 

14

NOTE 6. STOCKHOLDERS’ EQUITY

The following table summarizes the Company’s shares of common stock and preferred stock:SharesPar ValueAuthorizedIssuedOutstanding(in thousands)As of June 30, 2025Common stock (1)$0.001 290,000 138,144 138,144 Preferred stock$0.001 5,000 — — As of September 30, 2024Common stock$0.001 290,000 124,376 124,376 Preferred stock$0.001 5,000 — —      (1) Does not include shares of common stock into which the Avoro Pre-Funded Warrants may be exercised.As of June 30, 2025 and September 30, 2024, respectively, 10,081,964 and 11,492,293 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company’s 2013 and 2021 Incentive Plans, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  On November 25, 2024, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with an institutional and accredited investor for a private placement of pre-funded warrants to purchase shares of common stock with an exercise price of $0.001 per share (“Avoro Pre-Funded Warrants”). Pursuant to the Securities Purchase Agreement, the Company sold pre-funded warrants to purchase up to 917,441 shares of common stock at a purchase price of $27.25 per pre-funded warrant, for an aggregate value